Lysozyme, a mediator of sepsis, impairs the cardiac neural adrenergic response by nonendothelial release of NO and inhibitory G protein signaling

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 293, Issue 5, 2007, Pages

  Mink, Steven N ^a,c   Cheng, Zhao Qin ^a   Bose, Ratna ^a   Jacobs, Hans ^a   Kasian, Krika ^a   Roberts, Diane E ^a   Santos Martinez, Luis E ^b   Light, R Bruce ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^c HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Adrenergic receptors; Myocardial depression; Septic shock; Sympathetic response

Indexed keywords

ATROPINE; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; CYCLIC GMP; GUANINE NUCLEOTIDE BINDING PROTEIN; LYSOZYME; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PERTUSSIS TOXIN; TRITON X 100;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DOG; HEART RIGHT VENTRICLE; INOTROPISM; NONHUMAN; PRIORITY JOURNAL; SEPSIS;

ANIMALS; DOGS; ELECTRIC STIMULATION; ENDOTHELIUM, VASCULAR; GTP-BINDING PROTEINS; MURAMIDASE; MYOCARDITIS; NITRIC OXIDE; RECEPTORS, ADRENERGIC, BETA; SEPSIS; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM;

EID: 36148970021     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00502.2007     Document Type: Article

References (38)

1. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 357: 593-615, 2001.
2. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 365: 63-78, 2005.
3. Anonymous. Nitric oxide synthase (iNOS, bNOS, eNOS) inhibitors. In: Calbiochem Inhibitor Source Book. San Diego, CA: Calbiochem, 2004, p. 73.
4. Bettens KM, De Hert SG, Sys SU, Brutsaert DL. Role of the endocardial endothelium in the negative inotropic effects of thiopental. Anesthesiology 85: 1100-1110, 1996.
5. Blinks JR. Field stimulation as a means of effecting the graded release of autonomic transmitters in isolated heart muscle. J Pharmacol Exp Ther 151: 221-235, 1966.
6. Briggs RS, Perillie PE, Finch SC. Lysozyme in bone marrow and peripheral blood cells. J Histochem Cytochem 14: 167-170, 1972.
7. Burgess P, Appel SH, Wilson CA, Polk HC Jr. Detection of intra-abdominal abscess by serum lysozyme estimation. Surgery 115: 16-21, 1994.
8. 2-adrenergic dysfunction in canine myocardium. Cardiovasc Res 56: 225-234, 2002.
9. Danson EJ, Choate JK, Paterson DJ. Cardiac nitric oxide: emerging role for nNOS in regulating physiological function. Pharmacol Ther 106: 57-74, 2005.
10. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257: 387-389, 1992.
11. Fleming A. On a remarkable bacteriolytic element found in tissue and secretions. Proc R Soc Lond Biol 93: 306-307, 1922.
12. Garvey EP, Oplinger JA, Furfine ES, Furfine RJ, Kiff F, Laszlo F, Whittle BJ, Knowles RG. 1400W is a slow, tight binding and highly selective inhibitor of inducible nitric oxide synthase in vivo and in vitro. J Biol Chem 272: 4959-4963, 1997.
13. 3- Adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 21: 426-431, 2000.
14. Gomez A, Wang R, Unruh H, Light RB, Bose D, Chau T, Correa E, Mink S. Hemofiltration reverses left ventricular dysfunction during sepsis in dogs. Anesthesiology 73: 671-685, 1990.
15. G-methyl-L-arginine hydrochloride (546C88) in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit Care Med 27: 913-922, 1999.
16. Hah J, Roman LJ, Martasek P, Silverman RB. Reduced amide bond peptidomimetics. (4S)-N-(4-amino-5-[aminoalkyl]aminopentyl)-N′-nitroguanidines, potent and highly selective inhibitors of neuronal nitric oxide synthase. J Med Chem 44: 2667-2670, 2001.
17. Hansen NE, Karle H, Andersen V, Ølgaard K. Lysozyme turnover in man. J Clin Invest 51: 1146-1155, 1972.
18. Herring N, Paterson DJ. Nitric oxide-cGMP pathway facilitates acetylcholine release and bradycardia during vagal nerve stimulation in the guinea-pig in vitro. J Physiol 535: 507-518, 2001.
19. Jacobs H, Mink SN, Duke K, Bose D, Cheng ZQ, Howlett S, Ferrier GR, Light RB. Characterization of membrane N-glycan binding sites of lysozyme for cardiac depression in sepsis. Intensive Care Med 31: 129-137, 2005.
20. Jha P, Jacobs H, Bose D, Wang R, Yang J, Light RB, Mink S. Effects of E. coli sepsis and myocardial depressant factor on interval-force relations in dog ventricle. Am J Physiol Heart Circ Physiol 264: H1402-H1410, 1993.
21. Layland J, Li JM, Shah AM. Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat myocytes. J Physiol 540: 457-467, 2002.
22. Lee Y, Marletta MA, Martasek P, Roman LJ, Masters BS, Silverman RB. Conformationally-restricted arginine analogues as alternative substrates and inhibitors of nitric oxide synthases. Bioorg Med Chem 7: 1097-1104, 1999.
23. 3 activation depresses cardiac function in experimental sepsis. J Appl Physiol 85: 1693-1701, 1998.
24. Lohmann SM, Vaandrager AB, Smolenski A, Walter U, De Jonge HR. Distinct and specific functions of cGMP-dependent protein kinases. Trends Biochem Sci 22: 307-312, 1997.
25. Mason RP, Kubant R, Jacob RF, Walter MF, Boychuk B, Malinski T. Effect of nebivolol on endothelial nitric oxide and peroxynitrite release in hypertensive animals: role of antioxidant activity. J Cardiovasc Pharmacol 48: 862-869, 2006.
26. Massion PB, Pelat M, Belge C, Balligand JL. Regulation of the mammalian heart function by nitric oxide. Comp Biochem Physiol A Mol Integr Physiol 142: 144-150, 2005.
27. McCall TB, Feelisch M, Palmer RM, Moncada S. Identification of N-iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells. Br J Pharmacol 102: 234-238, 1991.
28. Mink SN, Bose R, Roberts DE, Jacobs H, Duke K, Bose D, Cheng ZQ, Light RB. Lysozyme binding to endocardial endothelium mediates myocardial depression by the nitric-oxide guanosine 3′,5′ monophosphate pathway in sepsis. J Mol Cell Cardiol 39: 615-625, 2005.
29. Mink SN, Jacobs H, Bose D, Duke K, Cheng ZQ, Liu G, Light RB. Lysozyme: a mediator of myocardial depression and adrenergic dysfunction in septic shock in dogs. J Mol Cell Cardiol 35: 265-275, 2003.
30. Mink SN, Jacobs H, Duke K, Bose D, Cheng ZQ, Light RB. N,N′,N″-triacetylglucosamine, an inhibitor of lysozyme, prevents myocardial depression in E. coli sepsis in dogs. Crit Care Med 32: 184-193, 2004.
31. National Institutes of Health. Guide for the Care and Use of Laboratory Animals. Bethesda, MD: National Institutes of Health, 1996. (NIH Publication No. 85-23.)
32. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100: 483-490, 1984.
33. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 76: 1539-1553, 1985.
34. Rupp H, Elimban B, Dhalla NS. Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 24 Suppl 1: S16-S24, 1994.
35. Schwarz P, Diem R, Dun NJ, Fostermann. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ Res 77: 841-848, 1995.
36. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 86: 49-86, 2000.
37. Shugar D. Measurement of lysozyme activity and the ultra violet inactivation of lysozyme. Biochim Biophys Acta 8: 302-309, 1952.
38. Tatsumi T, Keira N, Akashi K, Kobara M, Matoba S, Shiraishi J, Yamanaka S, Mano A, Takeda M, Nishikawa S, Asayama J, Fliss H, Nakagawa M. Nitric oxide-cGMP pathway is involved in endotoxin-induced contractile dysfunction in rat hearts. J Appl Physiol 96: 853-860, 2004.